Nextstellis Kit
Product Images NDC 51862-258

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nextstellis (NDC 51862-258). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nextstellis 01)

A horizontal bar chart showing the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC user (range 1 to 5), COC-User (range 3 to 9), Pregnancy (range 5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65. The chart highlights increasing risk levels from non-pregnant to postpartum status.*

FDA Label Image

Chemical Structure (Nextstellis 02)

A forest plot comparing the effect estimates of ever combined oral contraceptive (COC) use versus never use and current COC use versus never use across several studies. The horizontal axis shows effect estimates from -1.50 to 2.00. Confidence intervals are displayed for odds ratios (OR), relative risks (RR), and hazard ratios (HR) from multiple cohort studies dated 2002 to 2017.*

FDA Label Image

Chemical Structure (Nextstellis 03)

Chemical structure of drospirenone and estetrol shown as a molecular diagram, including various hydroxyl groups and ring structures, indicating the active ingredients of the product Nextstellis.*

FDA Label Image

Figure (Nextstellis 04)

Chemical structure of drospirenone, one of the active ingredients in the Nextstellis drug kit by Mayne Pharma.*

FDA Label Image

Figure (Nextstellis 05)

This is a diagram illustrating contraceptive effectiveness categorized by pregnancy rates per 100 women per year. It ranks methods from fewer pregnancies (less than 1 per 100 women) including implants, injections, intrauterine devices, and sterilization, to more pregnancies (85 or more per 100 women) with no birth control. Intermediate categories include birth control pills, skin patch, vaginal ring with hormones; condoms and diaphragm; and behavioral methods plus spermicides and withdrawal.*

FDA Label Image

Principal Display Panel (Kit Carton)

Illustration of the Nextstellis oral contraceptive pill kit showing four rows of pill slots arranged horizontally with arrows indicating the direction to take pills. The top row has a placeholder for placing a day label strip starting with the first day of the period. The kit includes 3 mg/14.2 mg drospirenone and estetrol tablets and features a start tab on the left side. Instructions indicate to follow the arrows when taking pills daily.*

FDA Label Image

Nextstellis 07

Nextstellis (drospirenone and estetrol) tablets 3 mg/14.2 mg in a kit packaging. The carton shows the product name, active ingredients, strength, and that it contains one blister card of 28 tablets with 24 active and 4 inert tablets. Distributed by Mayne Pharma, Greenville, NC. Storage instructions and safety information are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.